https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / J. Neurosurg. 2004 May;100(5 Suppl Pediatrics):492-72004-05-01 00:00:002021-11-15 15:38:16Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Int J Hyperthermia 2004 May;20(3):252-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Int J Hyperthermia 2004 May;20(3):252-772004-05-01 00:00:002019-02-15 08:35:13Feasibility of lung cancer hyperthermia using breathable perfluorochemical (PFC) liquids. Part I: Convective hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / J. Viral Hepat. 2004 May;11(3):217-24
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / J. Viral Hepat. 2004 May;11(3):217-242004-05-01 00:00:002019-02-15 08:37:51Selective functional deficit in dendritic cell–T cell interaction is a crucial mechanism in chronic hepatitis B virus infection
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Br. J. Haematol. 2004 May;125(3):343-52
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Br. J. Haematol. 2004 May;125(3):343-522004-05-01 00:00:002019-02-15 08:51:06Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-05-01 / Clin. Cancer Res. 2004 May;10(9):2944-53
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-05-01 / Clin. Cancer Res. 2004 May;10(9):2944-532004-05-01 00:00:002019-02-15 08:53:29Dendritic cell vaccination in medullary thyroid carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-15 / Clin. Cancer Res. 2004 Apr;10(8):2645-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-15 / Clin. Cancer Res. 2004 Apr;10(8):2645-512004-04-15 00:00:002019-02-15 08:39:06Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-07 / Am. J. Respir. Crit. Care Med. 2004 Jun;169(12):1322-30
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-07 / Am. J. Respir. Crit. Care Med. 2004 Jun;169(12):1322-302004-04-07 00:00:002019-02-15 08:50:36Cytotoxic T cell responses against mesothelioma by apoptotic cell-pulsed dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-01 / Expert Rev Vaccines 2004 Apr;3(2):163-70
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-01 / Expert Rev Vaccines 2004 Apr;3(2):163-702004-04-01 00:00:002004-04-01 00:00:00The role of idiotype vaccines in the treatment of human B-cell malignancies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-01 / Pneumologie 2004 Apr;58(4):210-6
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-01 / Pneumologie 2004 Apr;58(4):210-62004-04-01 00:00:002004-04-01 00:00:00[Evaluation of the therapeutic benefit of 41.8 degrees C whole body hyperthermia plus ifosfamide, carboplatin and etoposide (ICE) for patients with malignant pleural mesothelioma using the Modified Brunner-Score (MBS)]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2004-04-01 / Int. J. Clin. Oncol. 2004 Apr;9(2):85-91
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2004-04-01 / Int. J. Clin. Oncol. 2004 Apr;9(2):85-912004-04-01 00:00:002004-04-01 00:00:00Whole-body hyperthermia in combination with platinum-containing drugs in patients with recurrent ovarian cancer
